(Q44006461)

28 November 2017

title

Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer (English)

1 reference

positron emission tomography

28 November 2017

main subject

1 reference

1

1 reference

28 November 2017

6

Karen Siedlecki

1 reference

28 November 2017

9

Steven M Larson

1 reference

28 November 2017

10

Howard I Scher

1 reference

28 November 2017

Timothy Akhurst

2

1 reference

28 November 2017

Iman Osman

3

1 reference

28 November 2017

Rodolfo Nunez

4

1 reference

28 November 2017

Homer Macapinlac

5

1 reference

28 November 2017

David Verbel

7

1 reference

28 November 2017

Lawrence Schwartz

8

1 reference

28 November 2017

language of work or name

English

0 references

publication date

1 June 2002

1 reference

28 November 2017

1 reference

28 November 2017

volume

59

1 reference

28 November 2017

issue

6

1 reference

28 November 2017

page(s)

913-918

1 reference

Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer. A subanalysis of EORTC trial 30853. The EORTC Urological Group.

28 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901509-1

7 January 2021

Prostate specific antigen and gleason grade: an immunohistochemical study of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901509-1

7 January 2021

Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901509-1

7 January 2021

Preoperative staging of non-small-cell lung cancer with positron-emission tomography

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901509-1

7 January 2021

Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901509-1

7 January 2021

Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901509-1

7 January 2021

Metabolic flare: indicator of hormone responsiveness in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901509-1

7 January 2021

Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901509-1

7 January 2021

Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901509-1

7 January 2021

Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901509-1

7 January 2021

Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901509-1

7 January 2021

Positron emission tomography with 18fluorine-labelled deoxyglucose: utility in localized and advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901509-1

7 January 2021

Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography Is Useless for the Detection of Local Recurrence after Radical Prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901509-1

7 January 2021

Staging of pelvic lymph nodes in neoplasms of the bladder and prostate by positron emission tomography with 2-[(18)F]-2-deoxy-D-glucose.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901509-1

7 January 2021

Clinical trials in relapsed prostate cancer: defining the target

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901509-1

7 January 2021

Apples and oranges: building a consensus for standardized eligibility criteria and end points in prostate cancer clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901509-1

7 January 2021

Clinical states in prostate cancer: toward a dynamic model of disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901509-1

7 January 2021

Detection of bony metastases of androgen-independent prostate cancer by PET-FDG

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901509-1

7 January 2021

Benign versus malignant intraosseous lesions: discrimination by means of PET with 2-[F-18]fluoro-2-deoxy-D-glucose

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901509-1

7 January 2021

Pulmonary abnormalities and PET data analysis: a retrospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901509-1

7 January 2021

Application of the McNemar test to non-independent matched pair data

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901509-1

7 January 2021

Statistical issues in analysis of diagnostic imaging experiments with multiple observations per patient

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901509-1

7 January 2021

Note on the sampling error of the difference between correlated proportions or percentages

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901509-1

7 January 2021

How much can we rely on the level of prostate-specific antigen as an end point for evaluation of clinical trials? A word of caution!

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901509-1

7 January 2021

Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901509-1

7 January 2021

10.1016/S0090-4295(02)01509-1

Identifiers

DOI

1 reference

28 November 2017

1 reference